Gilead Withdraws Trodelvy in Bladder Cancer After Confirmatory Trial Failures

Gilead Sciences has decided to pull Trodelvy from the bladder cancer market after a confirmatory trial, TROPiCS-04, failed to show improved survival rates, leading to discussions with the FDA and the drug’s withdrawal[1][2]. Originally granted accelerated approval in 2021, Trodelvy was found lacking in efficacy compared to chemotherapy in advanced urothelial cancer patients, resulting in safety concerns due to adverse events[3][1]. Despite this setback, Trodelvy remains on the market for other indications, such as breast cancer, and is projected to contribute significantly to Gilead's future revenues.